Study of AL001 for treatment of patients with Post-Traumatic Stress Disorder (PTSD)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 13 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Mar 2025 According to an Alzamend Neuro media release, the company expects to initiate this trial in the fourth quarter of 2025 in collaboration with Massachusetts General Hospital as its contract research organization.
15 Nov 2023 According to an Alzamend Neuro media release, the company has submitted an investigational new drug application to the U.S. Food and Drug Administration for the initiation of study AL001-PTSD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for treatment of patients with PTSD.
15 Nov 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com